AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: Alexion, AstraZeneca Rare Disease (alexion.com)
Alexion manages to avoid high BS scores primarily through the ‘boring substance’ of regulatory compliance and clear citations. While the top-level copy is thick with pharma-fluff, the secondary layers provide the names, dates, and references required for industry credibility.
Populate the ‘Innovation’ sub-page with specific Phase I-III pipeline data to replace the current generic AI and Genomics blocks. Integrate Person schema for all named ‘Leading Voices’ to provide a verifiable digital footprint for their expertise. Replace the H1 power-word ‘Pioneering’ with a more specific verb that references a recent regulatory milestone or therapeutic area expansion. Add direct links to ClinicalTrials.gov for the ‘Patient-Centric Trial Design’ section to bridge the proof gap.
The site exhibits a moderate ratio of power words to specific nouns. High-fluff headings like [H2] Pushing the Boundaries of Science are countered by the inclusion of specific named experts such as Nick France, Seng Cheng, and Sophia Zilber. The body text provides concrete statistics on the ‘Living with Rare’ page, including the ‘1 in 2’ diagnosis ratio for children and ‘90%’ of rare diseases lacking approved treatments, which significantly anchors the marketing claims in reality.
Breadcrumbs, clusters, and parent child paths must exist in the HTML — not just in schema. Start your free link graph inspection and see whether your hierarchy survives a machine level crawl.
Minor drift is detected between the high-level ‘Innovation’ promises on the homepage and the actual sub-page content. The [H1] Innovation page is structurally thin with only 722 characters and three generic H3 categories (Data Science, Diagnostics, Genomics) without providing the technical depth promised by the hero section’s ‘Pioneering new possibilities’ claim. However, the ‘Living in Rare’ sub-page successfully delivers on the mission-driven signal of the homepage.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site avoids common trust theatre traps like unverified testimonials. While the review_count is 0, the proof_links_count is 1 on every major page, leading to a robust ‘References’ section on the ‘Living with Rare’ page that cites the Orphanet Journal of Rare Diseases and the EveryLife Foundation. The presence of Veeva IDs (e.g., Veeva ID: GL/ALL/0039) serves as a high-authority signal of regulatory compliance in the pharmaceutical industry.
The proof density is high for a corporate pharma site, particularly regarding disease awareness. The site provides 8 specific external references to validate its claims about the rare disease landscape. The ratio of vague assertions like ‘pioneering new possibilities’ is balanced by the ‘Rare Disease by the Numbers’ section which uses five distinct data points to ground the narrative.
For a demonstration of entity driven retail architecture, open the Walmart Structured Data audit. View the Walmart Structured Data Audit to see how product, brand, and service entities are reconstructed for AI systems.
Cliché density is the primary driver of the score, with heavy reliance on industry-standard phrases like ‘transforming patient outcomes,’ ‘patient-centric,’ and ‘science-driven solutions.’ The value proposition—’where science meets compassion’—is a standard pharmaceutical cliche that could be swapped with competitors like Sanofi Genzyme or Takeda. The template structure (About Us, Media, Research and Development) follows the standard big-pharma blueprint exactly.
Authority is well-established through the AstraZeneca affiliation and named ‘R&D Leading Voices.’ A small gap exists as these experts are not currently supported by Person schema or direct sameAs links to their academic or professional portfolios in the metadata. The technical implementation is professional, with clean heading hierarchies and Organization schema that includes social media sameAs links.
There is a slight disconnect between the ‘relentless sense of urgency’ claimed on the homepage and the lack of real-time pipeline updates or clinical trial result summaries on the ‘Innovation’ page. Most performance claims are backed by broad industry statistics rather than specific internal ‘Alexion-only’ performance metrics. However, the dated articles (as recent as May 21, 2026) suggest a current and active content footprint.
Medical Devices, Pharma & Biotech BS: Alexion, AstraZeneca Rare Disease (alexion.com)
The content perfectly aligns with the Pharma & Biotech category, specifically focusing on the rare disease therapeutic area. Evidence includes the use of Veeva IDs (GL/ALL/0071), mentions of regulatory pathways, and clinical trial design terminology.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The score of 28 reflects a 'Low BS' profile. Points were primarily deducted for Industry Cliché Density (Step 4) and the thin Information Density on the Innovation sub-page (Step 1). The site's adherence to pharma regulatory standards (Veeva IDs) and strong external proof paths on the living-in-rare page prevented a higher score.”